Efficacy and safety of lecanemab monoclonal antibody in the treatment of mild to moderate Alzheimer’s disease: a systematic review and meta-analysis
Background Lecanemab is a novel therapy for Alzheimer’s disease (AD), but comprehensive evidence is lacking. This systematic review and meta-analysis evaluated the efficacy and safety in AD. Methods Registered in PROSPERO (CRD420251146867). PubMed, Embase, Cochrane Library, Web of Science, and Scopus were searched for...